Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Not for human consumption, therapeutic use, or diagnostic application
Fifth, cost-effectiveness analyses are critical given the high price of current GLP-1 RAs and the large potential treatment population: preliminary health-economic models suggest acceptable cost-effectiveness ratios in high-fibrosis patients with comorbid type 2 diabetes and cardiovascular disease, but robust data in broader MASLD populations are lacking
Diabetes Care 38 , 132139 (2015)
Injections skip all of that
US$ 26.42
US$ 21.40
US$ 21.29
US$ 20.87
US$ 21.75
US$ 22.14
US$ 28.97
US$ 28.57
US$ 24.43
US$ 20.34
US$ 23.40
